All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Sara Ghorashian, University College London, London, UK. We asked, What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?
What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?
The COVID-19 pandemic has had an impact on the logistics of the already complex delivery of chimeric antigen receptor (CAR) T-cell therapies, by delaying both clinical studies and CAR T-cell accreditation for many centers. Ghorashian provides an overview of the challenges faced and dimensions to consider for the future, including vaccination, complications, and disease context.
COVID-19 vaccination for hematopoietic stem cell transplant patients
The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular, patients with hematologic malignancies have been...
When is it safe to schedule an allo-HSCT after COVID-19 infection?
During the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Maximilian Christopeit, University Hospital Tübingen,...
Subscribe to get the best content related to ALL delivered to your inbox